in the accumulation of autoantibodies. In autoimmune hepatitis (AIH), the presence of anti-Soluble Liver Antigen (SLA or SepSecs) autoantibodies is associated with significantly reduced overall survival, but the associated autoreactive CD4 T cells have not been characterized yet.
Introduction
The main feature of autoimmune disorders is an abnormal reactivity of the adaptive immune system against self-antigens. The detection of the resulting self-reactive autoantibodies is one of the main criteria for the diagnosis of autoimmune diseases. Antibody production results from a crosstalk between cognate antigen-specific B cells and CD4 T cells in response to a specific antigen. The CD4 T follicular helper (TFH) cell population, characterized by the expression of the chemokine receptor CXCR5 and of the activation marker PD1, has been identified as the main subset of CD4 T cells responsible for B cell help in antibody responses [1] [2] [3] [4] . However, the implication of TFH cells in human autoimmune activation
is not yet well characterized, and whether those cells carry self-antigen-reactive TCR has not been studied in many human autoimmune diseases [5] [6] [7] [8] [9] .
Autoimmune hepatitis (AIH) is a rare disease with an incidence range from 1 to 2 per 100 000 individuals in Europe. Like other autoimmune liver diseases (AILD), AIH is characterized by an immune attack targeting the liver and the accumulation of specific auto-antibodies (e.g. anti-SLA autoantibodies). A genetic predisposition linked to HLA class II alleles [10] [11] [12] suggests a predominant role of CD4 T cell subsets in driving autoantibody accumulation and disease progression. Indeed, in AIH, CD4 T cells infiltrate the liver 10, 13, 14 , yet it is still debated whether those pathogenic CD4 T cells are related to TH17 cells [15] [16] [17] , TFH cells 7, 8 or TNF producing cells 14 . In fact, the molecular signature of self-antigen-specific CD4 T cells in AIH has remained elusive due to the difficulty to track such rare cells 10, [18] [19] [20] [21] , like in other AILD and many autoimmune disorders.
Recent studies have identified B-helper PD-1 + CXCR5 -CD4 T cell populations, named T peripheral helper cell (TPH) or TH10 cells, which support antibody accumulation in rheumatoid arthritis (RA) through IL-21, or in systemic lupus erythematosus (SLE) through IL-10 production [22] [23] [24] [25] . Despite evidence for the accumulation of TPH or TH10 cells in their respective inflamed target tissue, it is still unknown whether they carry self-antigen-specific TCRs, a defining characteristic of autoreactive T cells.
Christophersen et al. characterized gluten-specific CD4 T cells and proposed a generic distinct
phenotype of CD4 T cell, based on the expression of PD-1 and the absence of CXCR5 expression, possibly involved in multiple autoimmune disorders such as systemic sclerosis, SLE and Celiac disease 18 . However, although phenotypes are similar, the transcriptomic signatures of identified pathogenic PD-1 + CXCR5 -CD4 T cells are different in RA 22 and in SLE 23 , and not known in AIH.
In AIH, immunosuppressive treatments induce complete remission but more than 70% of patients relapse when treatment withdrawal is attempted, suggesting a persistence of pathogenic cells such as autoreactive CD4 T cells 10, 26 . Moreover, the presence of anti-soluble liver antigen (SLA or SepSecs) autoantibodies in the blood of AIH patients is associated with significantly reduced overall survival 27 .
This suggest a link between the adaptive immunity (autoreactive CD4 T cell response) and the prognosis of the AIH. Thus, there is an urgent clinical need to identify new therapeutic options targeting both the persistence and function of self-reactive T cells in AIH. Here, we have used ex vivo restimulation assays and 5'-end single-cell RNA-seq to define the surface phenotype, gene expression profile, and TCRαβ repertoire of a total of 546 self-reactive CD4 T cells in five distinct AIH patients with anti-SLA autoantibodies. We report that circulating autoantigen-specific CD4 T cells invariably carry a memory PD-1 + CXCR5phenotype and a pro-inflammatory B-helper molecular and functional profile. Our study further identifies a specific T cell phenotypic signature which may be used as a blood biomarker of disease activity in all AIH patients.
Methods

Subject samples
All the patients eligible signed a written informed consent prior to inclusion and a bio-bank of samples from AIH patients (BioHAI) is maintained in Nantes University Hospital. All AIH patients had a simplified diagnostic score superior or equal to 6 according to the simplified scoring system for AIH of the international autoimmune hepatitis group (IAHG) 28 . All the patients received initially a standard immunosuppressive treatment protocol with corticosteroids (0.5-1 mg/kg). Azathioprine was added after two weeks (1-2 mg/kg) and monitored according to the tolerance of the patient. Corticosteroid treatment was then tapered until withdrawal. All the patients were screened for thiopurine S-methyltransferase (TPMT) genotyping before azathioprine administration. Untreated patients are new onset AIH patients enrolled at diagnosis prior any treatment initiation as previously described 13 . Treated / Active AIH patients are under standard treatment but do not normalize the transaminases (AST and ALT) or the serum IgG levels or present an active interface hepatitis in the liver biopsy. Treated / Complete remission AIH patients are defined biochemically by a normalization of the transaminases and the IgG levels, according to the most recent European clinical practice guidelines on AIH 29 .
Peptide re-stimulation assay
Peripheral blood mononuclear cells (PBMCs) from six SLA-pos (seropositive) and six SLA-neg (seronegative) AIH patients were tested for their reactivity against SLA and MP65 peptides (Candidas Albicans / C.Alb antigen used as positive control: common antigen with a TH17 signature). For the CD154 (CD40L) expression assay, 10 to 20x10 6 PBMCs (at a final concentration of 10x10 6 /mL) were stimulated for 3h at 37°C with 5µg/mL of synthesized peptide pools (20 amino PE anti-CD152 (CTLA4, BNI3, BD Biosciences), Alexa Fluor 700 anti-IFNG (B27, BD Biosciences) and PE anti-IL21 (3A3-N2.1, BD Biosciences) antibodies were used for intra-cellular staining by using the Fixation/Permeabilization Solution Kit (BD Cytofix/Cytoperm™, BD Biosciences). For in vitro intracellular cytokine staining, cells were restimulated with 100 ng/mL phorbol 12-myristate 13-acetate and 1 µg/mL ionomycin in the presence of 10 mg/mL Brefeldin-A for 4 hours at 37ºC prior surface and intra-cellular staining.
Single cell RNA sequencing and analysis (scRNAseq)
First, CD154 + memory CD4 T cells were sorted on BD FACSAriaII, one cell per well, in 96-well plates containing specific lysis buffer at the CRTI, Nantes. Plates were immediately frozen for storage at -80°C, and sent on dry ice to the Genomics core facility of CIML, Marseille, for further generating scRNAseq libraries with the FB5P-seq protocol as described 30 . Briefly, mRNA reverse transcription (RT), cDNA 5'end barcoding and PCR amplification were performed with a template switching (TS) approach. After amplification, barcoded full-length cDNA from each well were pooled for purification and library preparation. For each plate, an Illumina sequencing library targeting the 5'-end of barcoded cDNA was prepared by a modified transposase-based method incorporating a plate-associated i7 barcode.
Resulting libraries had a broad size distribution, resulting in gene template reads covering the 5'-end of transcripts from the 3 rd to the 60 th percentile of gene body length on average. As a consequence, sequencing reads cover the whole variable and a significant portion of the constant region of the TCRα and TCRβ expressed mRNAs, enabling assembly and reconstitution of TCR repertoire from scRNAseq data.
Cells were analyzed in three distinct scRNAseq experiments (Extended Table 1 ). Libraries prepared with the FB5P-seq protocol were sequenced on Illumina NextSeq550 platform with High Output 75 cycles flow cells, targeting 5x10 5 reads per cell in paired-end single-index mode with the following configuration: Read1 (gene template) 67 cycles, Read i7 (plate barcode) 8 cycles, Read2 (cell barcode and Unique Molecular Identifier) 16 cycles.
We used a custom bioinformatics pipeline to process fastq files and generate single-cell gene expression matrices and TCR sequence files, as described 30 . Briefly, the pipeline to obtain gene expression matrices was adapted from the Drop-seq pipeline 31 , relied on extracting the cell barcode and UMI from Read2 and aligning Read1 on the reference genome using STAR and HTSeqCount. For TCR sequence reconstruction, we used Trinity for de novo transcriptome assembly for each cell based on Read1 sequences, then filtered the resulting isoforms for productive TCR sequences using MigMap, Blastn and Kallisto. Briefly, MigMap was used to assess whether reconstructed contigs corresponded to a productive V(D)J rearrangement and to identify germline V, D and J genes and CDR3 sequence for each contig. For each cell, reconstructed contigs corresponding to the same V(D)J rearrangement were merged, keeping the largest sequence for further analysis. We used Blastn to align the reconstructed TCR contigs against reference sequences of constant region genes, and discarded contigs with no constant region identified in-frame with the V(D)J rearrangement. Finally, we used the pseudoaligner Kallisto to map each cell's FB5P-seq Read1 sequences on its reconstructed contigs and quantify contig expression. In cases where several contigs corresponding to the same TCR chain had passed the above filters, we retained the contig with the highest expression level.
Quality control was performed on each scRNAseq batch independently to remove poor quality cells. Cells with less than 250 genes detected were removed. We further excluded cells with values below 3 median absolute deviations (MADs) from the median for UMI counts, for the number of genes detected, or for ERCC accuracy, and cells with values above 3 MADs from the median for ERCC transcript percentage, as described 30 . The number of cells passing quality control, mean sequencing depth, and mean gene detection for each batch is shown in Extended Table 1 .
All cells passing quality control were analyzed together with custom scripts in the R programming language (available upon request). For each cell, gene expression UMI count values were log normalized with Seurat v3.0.0.9 32 NormalizeData with a scale factor of 10,000. Four thousand variable genes were identified with Seurat FindVariableFeatures, of which TCR coding genes were removed, yielding 3919 variable genes for further analyses. After data centering with Seurat ScaleData, principal component analysis was performed on 3919 variable genes with Seurat RunPCA, and embedded in two-dimensional tSNE with Seurat RunTSNE on 40 principal components. Differentially expressed genes between C.Alb-specific and SLA-specific T cells were identified with Seurat FindAllMarkers which computes a likelihood-ratio test for single-cell gene expression (test.use='bimod), with an adjusted pvalue cutoff of 0.05. Gene expression heatmaps and plots showing PCA or tSNE embeddings colored by gene expression levels or metadata were plotted with custom functions and ggplot2 ggplot.
Following in silico reconstruction of TCR sequences from scRNAseq reads, functional variable TCRα or TCRβ sequences were recovered for 79%, 75% and 54% of cells passing gene expression quality control in the three scRNAseq experiments, respectively (Extended Table 1 ). Nucleotide sequences were submitted to IMGT HighV-QUEST analysis 33 to identify V and J genes, CDR3 junction sequence, and other TCR sequence features. We further processed the IMGT HighV-QUEST output summary Cells for which only one of the two sequences was available were joined to a TCRαβ clonotype based only on its TCRα or TCRβ clonotype identity. Clonotype identity for each cell was added as a metadata to the Seurat scRNAseq dataset for visualization in tSNE embeddings.
TCR sequencing
CCR6 -CD4 T cell subsets were sorted on a BD FACSAriaII. gDNA were extracted with NucleoSpin® Blood kit (Macherey-Nagel) and TCR sequencing was performed by Adaptive Biotechnologies R (Seattle, USA).
B cell co-culture assay
Total B cells (CD19 + CD4 -CD3 -), PD-1 + CXCR5 -CD45RAand PD-1 -CXCR5 -CD45RA -CD4 T cells were sorted on BD FACSAriaII. Sorted cell subsets were co-cultured at a ratio 1:1 in 200µL RPMI/10% FBS and stimulated with CytoStim™ (Miltenyi Biotec). After 7 days' culture, supernatants were collected and total IgG measured by ELISA (eBioscience). Plasmablasts (CD19 + CD38 + CD27 + ) percentage was analyzed by flow cytometry. For blocking experiments, 20µg/mL IL-21 R Fc Chimera (R&D Systems) was used.
Unsupervised flow cytometry analysis
Flow cytometry data from 22 patients (11 active AIH and 11 NASH) were generated the same day and first analyzed using FlowJo 10.6.0 (TreeStar Inc) to extract the same number of viable lymphoid CD3+ cells (27.10 3 per patients; total of 594.10 3 ). New FCS folders were generated with identical CD3+ T cell number to performed unsupervised clustering analysis. FlowSOM package on R was used to generate 400 clusters. Metaclustering was performed by using WGCNA package. Heat-maps were generated by using complex heat map package. Wilcoxon test was used to identify significant variation between active AIH and NASH patients.
Statistical analysis
Statistical comparisons were performed as indicated in figure legends. P value <0.05 after adjustment were considered significant.
Accession codes
The single-cell RNA-seq data generated in the current study are available in the Gene Expression
Omnibus database under accession code GSExxxxxx.
Results
SLA-specific CD4 T cells are detectable in the blood of seropositive (anti-SLA+) AIH patients and present a memory PD-1 + CXCR5phenotype. To directly identify autoreactive CD4 T cells based on
their antigen specificity, we performed an ex vivo short stimulation assay on PBMC with a pool of antigen-derived overlapping peptides, followed by an enrichment step of antigen-specific CD154 + T cells [34] [35] [36] (Extended Data Figure 1) . We analyzed AIH patients with (SLA-pos) and without (SLA-neg) anti-SLA autoantibodies and detected SLA-specific CD4 T cells only in SLA-pos patients, whereas control C.Alb-specific CD4 T cell counts were similar in both groups (Figure 1a and b and Table 1 ).
The SLA-specific CD4 T cell population frequency was stable in longitudinal analysis of two SLA-pos AIH patients (Extended Data Figure 1 ).
Both SLA-and C.Alb-specific CD4 T cells exhibited a memory phenotype but differed for the expression of CCR6 and PD-1 (Figure 1c and Extended Data Figure 1) . C.Alb-specific CD4 T cells were PD-1 -CXCR5 -CCR6 + , consistent with their expected TH17 phenotype [36] [37] [38] . Autoreactive SLA-specific CD4 T cells were PD-1 + CXCR5 -CCR6and express CD27 (Extended Data Figure 1) . Neither SLA-nor C.Albspecific CD4 T cells showed high CXCR5 expression, suggesting they were distinct from circulating TFH CD4 T cells, classically involved in the B cell differentiation process 1, 39 .
scRNA-seq analysis reveals a TPH-like profile of auto-reactive CD4 T cells. Next we submitted ex vivo activated C.Alb-specific and SLA-specific memory CD4 T cells from 5 SLA-pos AIH patients to FACS-based 5'-end single-cell RNA-seq analysis for parallel analysis of gene expression and TCRαβ sequence 30 (Figure 2a) . Unsupervised analysis of the single-cell gene expression profiles revealed a clear distinction between the two antigen-specific memory T cell subsets (Figure 2b) . A total of 211 genes were differentially expressed between C.Alb-specific and SLA-specific CD4 T cells (Figure 2c and d and Extended Table 2 ). The molecular profiles of C.Alb-specific and SLA-specific CD4 T cells were robust and stable in a longitudinal analysis of samples from one patient collected at 3 time points over a 6-month period (Figure 2c) .
One advantage of the short restimulation assay is to allow transcriptomic characterization of the cytokine expression profile of antigen-specific CD4 T cells 34 (Figure 2d and e) . C.Alb-specific CD4 T cells showed a typical TH17 cytokine profile 37, 40 with high expression of IL17A, IL23A, CCL20, CSF2 (GM-CSF), IL2 and TNF among other genes. C.Alb-specific CD4 T cells were characterized by the expression of the transcription factors FOSL2, MYC and EGR2, characteristic genes expressed in the TH17 lineage 37, 40 (Figure 2d and e and Extended Table 2 ). C.Alb-specific CD4 T cells also expressed genes encoding the surface immune markers CD200, ICOS, IL7R (CD127) and TNFRSF4 (OX40). By contrast, restimulated circulating autoreactive SLA-specific CD4 T cells had a distinct B-helper (IL21) and proinflammatory (IFNG and TNF) gene signature (Figure 2d and e and Extended Table 2 ). This B-helper profile was also conferred by the expression of the transcription factor MAF and by the expression of genes encoding surface immune markers such as ICOS, TIGIT, CTLA4 and SLAMF6, which were previously found to be elevated on both TFH and TPH cells 22, 41 . SLA-specific CD4 T cells did not express CXCR5 (Figure 1) and expressed IFNG suggesting their molecular signature was closer to the reported TPH signature (CD200, IL21, IFNG, ICOS, TIGIT, CTLA4, ITM2A, SLAMF6 and MAF) than to a TFH signature 22, 24, 25 . However, SLA-specific CD4 T cells specifically expressed some additional genes not previously reported in studies of human autoimmune TPH or TFH cells: the transcription factor NR3C1, a glucocorticoid receptor involved in immune-regulation processes 42 ; CD109, an inhibitor of the TGF-β pathway 43, 44 and also involved in the regulation of inflammation 45 ; CLEC2D and KLRB1, involved in the regulation of the innate immune response 46 ; and ITGA4 (CD49d) and ITGB1, which together form the complex VLA-4. Thus, autoreactive CD4 T cells in AIH share a transcriptomic signature with the previously reported TPH cell population but differ for the expression of additional immune regulatory genes.
With the 5'-end scRNA-seq method we were able to reconstruct paired variable TCRα/TCRβ sequences in silico and link them to the transcriptome of antigen-specific CD4 T cells (Figure 2a) . In all patients, SLA-and C.Alb-specific CD4 T cells were polyclonal, yet we consistently identified some highly frequent TCRαβ clonotypes indicative of antigen-specific clonal expansions (Figure 2f) . We found no evidence for public TCR rearrangements in SLA-and C.Alb-specific CD4 T cells from these five AIH patients (Extended Table 3 ). T cells from the same TCRαβ clonotype were transcriptionally diverse within the overall molecular profile associated with their antigen-specificity (Figure 2g) , which was conserved across patients despite some detectable sample-related batch effects (Figure 2h) .
The PD-1 + CXCR5 -CD4 T cell population is the reservoir of auto-reactive CD4 T cells in AIH.
Given the B-helper molecular profile and PD-1 + CXCR5surface phenotype of ex vivo activated SLA-specific CD4 T cells, we set out to more precisely identify the phenotypic niche of autoreactive CD4 T cells in the peripheral blood of AIH patients. Bulk TCRβ sequencing was performed on sorted memory PD-1 + CXCR5 -CCR6 -, PD-1 -CXCR5 -CCR6 + and PD-1 -CXCR5 -CCR6 -CD4 T cell subsets sampled at three different time points from the same patient (Extended Data Figure 2) . SLA-specific TCRβ clonotypes identified at the single-cell level were then tracked in the bulk datasets and found to be restricted to the PD-1 + CXCR5 -CCR6 -CD4 T cell population (Figure 3a) . In contrast, C.Alb-specific TCRβ clonotypes were restricted to the PD-1 -CXCR5 -CCR6 + CD4 T cell population (Figure 3b) . The relative frequency of TCRβ clonotypes was stable in longitudinal sampling across 6 to 8 months, both for SLA-and C.Alb- Figure 2b and c) . These results clearly demonstrate that the PD-1 + CXCR5 -CD4 T cell population is the major peripheral reservoir of autoreactive CD4 T cells in AIH.
specific CD4 T cells (Extended Data
Memory PD-1 + CXCR5 -CD4 T cells are enriched in the blood of AIH patients.
We compared the immune phenotype of PBMC between patients with an active AIH (n=28, treated or not) and patients with Non-Alcoholic SteatoHepatitis (NASH) with no sign of autoimmunity (n=18) (Figure 3c and Table   2 ). The proportion of PD-1 + CXCR5cells amongst the memory CD4 T cell population was increased in AIH patients and exceeded that of the PD-1 + CXCR5 + TFH cell population (Figure 3c) .
The PD-1 + CXCR5 -CD4 T cell population has a TPH-like phenotype and function in AIH.
Next, we established the phenotypic link between SLA-specific CD4 T cells and the peripheral PD-1 + CXCR5memory CD4 T cell population in a group of AIH patients independent of their anti-SLA antibody serology. Recent studies have reported phenotypic and functional similarities between blood memory PD-1 + CXCR5 -CD4 TPH cells and PD-1 + CXCR5 + CD4 TFH cells 22 . In AIH patients, both PD-1 + CXCR5and PD-1 + CXCR5 + memory CD4 T cells were TIGIT high CD127 low CD49d high and expressed ICOS and CTLA4, similar to SLA-specific CD4 T cells (Figure 3d and Extended Data Figure 3 ). Yet we found major differences regarding their capacity to produce IFNγ and IL-21 upon ex vivo restimulation. In PD-1 + CXCR5 -CD4 T cells, 38.3 +/-17.3 % cells produced IFNγ, and more than half of IL-21 producing cells also produced IFNγ. In contrast, only 10.8 +/-5.2 % of PD-1 + CXCR5 + TFH produced IFNγ and most IL-21 producing TFH cells did not produce IFNγ (Figure 3e) . These results are consistent with the proinflammatory profile of pathogenic PD1 + CXCR5 -CD4 T cells and SLA-specific CD4 T cells. To test the B helper capacity of PD-1 + CXCR5 -CD4 T cells from AIH patients (n=8; one experiment per patient), we sorted PD-1 + CXCR5and PD-1 -CXCR5memory CD4 T cells and co-cultured them with autologous B cells in the presence of a super-antigen (Figure 3f-h) . Memory PD-1 + CXCR5 -CD4 T cells from AIH patients were more potent than PD-1 -CXCR5 -CD4 T cells at inducing the differentiation of B cells into CD27 + CD38 + plasmablasts (Figure 3f) and IgG secretion (Figure 3g) . Blocking soluble IL-21 with decoy IL-21R in those co-cultures drastically reduced the proportion of differentiated plasmablasts (Figure 3h) , suggesting that the B-helper capacity of PD1 + CXCR5 -CD4 T cells in AIH patients was mostly IL-21dependent.
PD-1 and CD38 as potential blood markers of an active AIH. In a parallel effort to determine the clinical relevance of tracking the autoreactive CD4 T cell population and to more precisely delineate its specific phenotype, we performed 11-color flow cytometry on peripheral blood T cells from 11 patients with an active AIH versus 11 patients with Non-Alcoholic SteatoHepatitis (NASH) ( Table 2) , monitoring markers identified in the scRNA-seq data or in previous phenotypic observations (Figure 1, 2 and 3) , with a focus on activation and differentiation markers (CD38, CD127 and CD27). Unsupervised analysis of these data with self-organizing maps (Extended Data Figure 4 ) and hierarchical clustering (Extended Data Figure 5 ) identified 14 phenotypic T cell metaclusters (Figure 4a) . Three metaclusters were significantly increased in AIH patients compared to NASH patients (Figure 4b) . Those three clusters were respectively memory CD4 + , CD8 + and double negative T cells, and all shared the PD-1 + CD38 + CXCR5 -CCR6 -CD127 -CD27 + phenotype (Figure 4c and Extended Data Figure 6) . With a focus on the CD4 T cell population, the frequency of PD-1 + CD38 + CXCR5 -CCR6 -CD127 -CD27 + memory CD4 T cells was significantly high in AIH patients with active disease compared not only to NASH patients, but also to AIH patients in complete remission under treatment (Figure 4d and Extended Data   Figure 7 ). This latter difference was not observed for the frequency of the broader PD1 + CXCR5memory CD4 T cell subset (Figure 4e) . Moreover, with ROC curve analyses, we observed that only the frequency of PD1 + CD38 + CXCR5 -CCR6 -CD127 -CD27 + memory CD4 T cells could discriminate active AIH from AIH patients in complete remission under treatment (AUC=0.73; p=0.08); this was not possible with the frequency of global PD1 + CXCR5memory CD4 T cells (AUC=0.62; p=0.19) (Figure 4f and g) . Finally, and Interestingly, the frequency of PD1 + CD38 + CXCR5 -CCR6 -CD127 -CD27 + memory CD4 T cells was better correlated to the serum IgG level than the frequency of the PD1 + CXCR5memory CD4 T cell subset (Figure 4h and i) . These analyses suggested that tracking peripheral blood CD4 T cells expressing this combination of markers could be used as a specific biomarker of AIH activity, and should be evaluated for clinical use in AIH and in other autoimmune disorders.
Discussion
The combination of the restimulation assay with scRNA-seq, further confirmed by bulk TCRseq, provided strong evidence that the memory PD-1 + CXCR5 -CCR6 -CD27 + CD4 T cell population, with Bhelper function and a pro-inflammatory signature, is the reservoir of autoreactive CD4 T cells in AIH.
This subset supports B cell differentiation through the production of IL-21, which constitutes a new possible therapeutic target for AIH treatment. These results confirm the idea that pathogenic CD4 T cells supporting B cell differentiation in multiple autoimmune disorders share a similar phenotype characterized by the expression of PD-1 and the absence of CXCR5, comparable to the recently described gluten-specific CD4 T cells in celiac disease 18 , TPH cells or TH10 cells in rheumatoid arthritis and in lupus [22] [23] [24] [25] . This suggest these cells are not from the classical TFH cell population 18, [22] [23] [24] [25] . We observed some differences between our study on AIH patients and previous studies on gluten-specific CD4 T cells 18 , autoreactive CD4 T cell described in infants with autoimmune diabetes 20 and expanded effector CD4 T cells in rheumatoid arthritis 47 . For instance, the PD-1 + CXCR5memory CD4 T cell population identified in our study expressed CD27 but did not express the chemokine receptor CCR6.
For the first time we propose a complete transcriptomic analysis of autoreactive (SLA-specific) CD4 T cells in AIH, and we reveal their specific molecular signature characterized by an IL21 and IFNG cytokine signature, resembling TFH (IL21) and TPH (IL21 and IFNG) cytokine profiles 22, 39, 41 . This transcriptomic signature seems to be disease-specific, although similarities with other pathogenic CD4 T cells involved in several autoimmune disorders were observed. Indeed, in autoimmune disorders, distinct pathogenic CD4 T cell molecular signatures have been reported, including a TFH and TPH signature 5, 6, 9, 18, 22, 24, 25 , a TH10 and Tr1/Treg 23, 48, 49 (regulatory T cell) signature, and a TH17-like signature 16, 19, 20, 38, 50 . Here, we have shown that SLA-specific CD4 T cells had a transcriptomic signature close to the TPH signature 22, 24, 25 (IFNG, IL21, MAF, CD200, ICOS, CTLA4, ITM2A, TIGIT and SLAMF6). However, CXCL13, one of the major genes characterizing TPH cells, was only detected in a small fraction of SLAspecific T cells. SLA-specific CD4 T cells express IRF4, STAT3, ICOS, CTLA4 and TIGIT like TH10 cells in SLE patients 23 or autoreactive TH17-like cells in MS patients 19 , but their signature was clearly distinct with low expression of IL10, GZMB, GNLY, IL17, CSF2, IL23A and FOSL2. Finally, we can conclude that SLA-specific CD4 T cells express a specific transcriptomic signature characterized by the transcription factors NR3C1, EGR2, STAT4, STAT3, IRF4 and MAF; the cytokines IL21, IFNG and TNF; and the immune-regulatory molecules CLEC2D, CTLA4, TIGIT, KLRB1 and CD109. These observations demonstrate that SLA-specific CD4 T cells in AIH have a specific molecular profile which partially overlaps with that of recently described TPH cells, and suggest a disease dependent immune signature of autoreactive CD4 T cells. Thus, the direct characterization of the transcriptomic signature of autoreactive CD4 T cells in diverse autoimmune disorders is primordial to elucidate the physiopathology of these cells.
The expression of PD-1 and the overexpression of genes related to immune regulation (NR3C1, TIGIT and CTLA4) could result from the chronic activation of autoreactive CD4 T cells. However, those autoreactive CD4 T cells persist with a pro-inflammatory profile (IFNG and TNF), which suggests a form of resistance or adaptation, rather than functional exhaustion. Thus, targeting these pathways (including CD109, a regulator of the TGFβ pathway and of inflammation, or CLEC2D and KLRB1, regulator of the NK killing function) may be interesting new therapeutic options. NK cells are enriched in the liver compared to blood 51 and a recent study has shown the presence of high numbers of KLRB1 + CD4 T cells with a pro-inflammatory cytokine signature (TNF and IFNG) in the inflamed liver 52 . This suggests that the NK-like signature we observed for autoreactive CD4 T cells in AIH may be imprinted by liverspecific factors.
Finally, based on the data generated from the scRNA-seq and from the phenotype analysis of circulating PD-1 + CXCR5 -CD4 T cells in AIH patients, we have identified a complete specific phenotype of memory CD4 T cells (PD-1 + CD38 + CD27 + CD127 -CXCR5 -) associated with an active AIH and linked to serum IgG level. This discovery has immediate clinical relevance for monitoring autoreactive T cells in a small volume of blood during clinical follow-up. The high rate of relapse after immunosuppressive treatment withdrawal is a major challenge when wishing to limit long term immunosuppression and associated side effects in AIH patients. However, classical biological tests (serum transaminases and IgG levels) are not powerful enough to anticipate relapse events. Thus, the capacity to track autoreactive T cell activity in patients' blood will be of interest for better treatment management in the clinic. 
